Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37106799 | 1.00 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL22200929 | 1.00 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL26623041 | 0.93 | BRD3 (0.42) | LMNAKDM4EPOLBMAPTBRD3 | |
| SCHEMBL24728401 | 0.89 | LMNA (0.43) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL30138591 | 0.89 | LMNA (0.43) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL26471064 | 0.88 | KDM4E (0.36) | LMNAKDM4EPOLBMAPTCRBN | |
| SCHEMBL30841804 | 0.88 | KDM4E (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL30221837 | 0.87 | BRD3 (0.31) | LMNAKDM4EPOLBMAPTBRD3 | |
| SCHEMBL30221744 | 0.87 | BRD3 (0.31) | LMNAKDM4EPOLBMAPTBRD3 | |
| SCHEMBL26623051 | 0.87 | BRD3 (0.31) | LMNAKDM4EPOLBMAPTBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375594-A | Preparation process of irinotecan intermediate | 山东恒屹生物医药有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | claimed |
| JP-8337584-A | — | — | None | — | — | JP | disclosed |
| WO-2025024697-A1 | INTERMEDIATES FOR SYNTHESIZING EXATECAN MESYLATE | SIGMA-ALDRICH CO. LLC (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-117865839-A | New method for preparing antibody-drug conjugate | 第一三共株式会社 | 2024-04-12 | — | — | CN | disclosed |
| CN-117838880-A | New method for preparing antibody-drug conjugate | 第一三共株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-117838881-A | New method for preparing antibody-drug conjugate | 第一三共株式会社 | 2024-04-09 | — | — | CN | disclosed |
| US-20240082418-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-03-14 | — | — | US | disclosed |
| CN-111065621-B | New method for preparing antibody-drug conjugate | 第一三共株式会社 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024020536-A1 | HEXACYCLIC TOPOISOMERASE INHIBITORS HAVING CYTOTOXIC ACTIVITY ON CANCER CELLS | NJ BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230381332-A1 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | BAILI BIO CHENGDU PHARMACEUTICAL CO LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| US-6552197-B2 | Condensed-hexacyclic compounds and a process therefor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-6504029-B1 | Reacting methanesulfonic acid with camptothecins, then crystallization and isomerization to obtain hydrophylic, filterable and soluble isomers | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | disclosed |
| EP-0811603-B1 | AMINOTETRALONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20010034446-A1 | Condensed-hexacyclic compounds and a process therefor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-25 | — | — | US | disclosed |
| EP-0737686-B1 | Camthothecin derivative with antitumor activity | DAIICHI SEIYAKU CO (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5849945-A | Aminotetralone derivatives and preparation process thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0811603-A1 | AMINOTETRALONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
| JP-H08337584-A | CONDENSED SIX-MEMBERED CYCLIC AMINO COMPOUND, MEDICINE CONTAINING THE SAME AND PRODUCTION OF THE SAME | DAI ICHI SEIYAKU CO LTD | 1996-12-24 | — | — | JP | disclosed |
| EP-0737686-A1 | Camthothecin derivative with antitumour activity | Daiichi Pharmaceutical Co., Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381332-A1 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | DCTD, CD38, CDA | LMNA 4180/4885KDM4E 2141/4885POLB 1960/4885 |
| US-20010034446-A1 | Condensed-hexacyclic compounds and a process therefor | CYP51A1, CYP4F11, FAR1 | LMNA 2624/4885KDM4E 4524/4885POLB 3419/4885 |
| US-20240082418-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | CD79B, FCGRT, C1R | LMNA 2305/4885KDM4E 1562/4885POLB 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.